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Abstract  Current  guidelines  differ  slightly  on  the  recommendations  for  treatment  of  Chronic
Obstructive  Pulmonary  Disease  (COPD)  patients,  and  although  there  are  some  undisputed  recom-
mendations,  there  is  still  debate  regarding  the  management  of  COPD.  One  of  the  hindrances  to
deciding which  therapeutic  approach  to  choose  is  late  diagnosis  or  misdiagnosis  of  COPD.  After
a proper  diagnosis  is  achieved  and  severity  assessed,  the  choice  between  a  stepwise  or  ‘‘hit
hard’’ approach  has  to  be  made.  For  GOLD  A  patients  the  stepwise  approach  is  recommended,
whilst for  B,  C  and  D  patients  this  remains  debatable.  Moreover,  in  patients  for  whom  inhaled
corticosteroids  (ICS)  are  recommended,  a  step-up  or  ‘‘hit  hard’’  approach  with  triple  therapy
will depend  on  the  patient’s  characteristics  and,  for  patients  who  are  being  over-treated  with
ICS, ICS  withdrawal  should  be  performed,  in  order  to  optimize  therapy  and  reduce  excessive
medications.
This paper  discusses  and  proposes  stepwise,  ‘‘hit  hard’’,  step-up  and  ICS  withdrawal  ther-
apeutic approaches  for  COPD  patients  based  on  their  GOLD  group.  We  conclude  that  all
approaches  have  beneﬁts,  and  only  a  careful  patient  selection  will  determine  which  approach
is better,  and  which  patients  will  beneﬁt  the  most  from  each  approach.
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Introduction
Current  guidelines  differ  slightly  on  the  recommendations
for  treatment  of  Chronic  Obstructive  Pulmonary  Disease
(COPD)  patients,  mainly  because  patient  stratiﬁcation  is  not
consensual  across  guidelines.1--5 Although  there  are  some
undisputed  recommendations,  such  as  smoking  cessation,
physical  activity  programs,  and  inﬂuenza  and  pneumococcal
vaccination,  there  is  still  debate  regarding  the  manage-
ment  of  COPD.6--12 The  therapeutic  approach  proposed  by
the  Global  Initiative  for  Chronic  Obstructive  Lung  Disease
(GOLD),  and  based  solely  on  the  GOLD  classiﬁcation  of
COPD,2 is  not  entirely  satisfactory,  given  the  variability
within  GOLD  groups,  namely  regarding  hospitalizations  and
mortality.13 However,  therapy  has  to  be  based  on  some  clas-
siﬁcation  system,  and  the  GOLD  classiﬁcation  is  the  most
widely  accepted,  even  with  its  caveats.
One  of  the  hindrances  to  deciding  which  therapeutic
approach  to  choose  is  late  diagnosis  or  misdiagnosis  of
COPD.  Patients  who  are  not  diagnosed  at  the  early  stages
of  the  disease  cannot  receive  the  early  treatment  which
has  been  shown  to  be  beneﬁcial.6,11,14 On  the  other  hand,
patients  misdiagnosed  with  asthma  or  Asthma-COPD  overlap
syndrome  (ACOS),  will  be  overtreated  with  inhaled  corti-
costeroids  (ICS),  and  are  likely  to  see  no  improvement  in
their  symptom  burden.  In  fact,  two  recent  analyses  showed
that,  in  current  clinical  practice,  ICS  are  being  prescribed
inappropriately,15,16 and  that  thousands  of  patients  may  be
overtreated.
After  a  proper  diagnosis  is  achieved,  and  severity
assessed,  the  choice  for  a  stepwise  or  ‘‘hit  hard’’  approach
has  to  be  made,  and  if  for  GOLD  A  patients  the  step-
wise  approach  is  recommended,2 for  B,  C  and  D  patients
this  remains  debatable.17 The  argument  for  the  stepwise
approach  is  to  not  overtreat  patients,  but  some  patients
may  beneﬁt  from  a  ‘‘hit  hard’’  approach,  with  the  aim
of  maximal  bronchodilation.12,13,18--20 In  patients  who  will
beneﬁt  from  dual  bronchodilation,  a  long-acting  mus-
carinic  antagonist/long-acting  beta-agonist  (LAMA/LABA)
ﬁxed-dose  combination  is  advantageous.11,12,21--24 Also,  in
patients  for  whom  ICS  is  recommended,  a  step-up  or
‘‘hit  hard’’  approach  with  triple  therapy  will  depend  on
the  patient’s  characteristics.2,4,5,17 For  patients  who  are
being  overtreated  with  ICS,  ICS  withdrawal  should  be  per-
formed,  in  order  to  optimize  therapy  and  reduce  excessive
medications.21,22,25--28 However,  this  raises  another  question:
how  to  decide  when  a  patient  is  being  overtreated?  There
are  currently  no  reliable  or  accurate  biomarkers  of  response
to  therapy  and  disease  progression,  so  the  decision  concern-
ing  ICS  withdrawal  must  be  based  on  the  available  objective
tests  and  subjective  instruments.2
Results  from  a  recent  UK  Primary  Care  Setting  retrospec-
tive  study  showed  that,  24  months  after  COPD  diagnosis  and
prescription  of  initial  therapy,  several  treatment  strategies
are  used:  switch  in  medication,  stepwise,  step-up  and  ICS
withdrawal,28 suggesting  that  here  is  an  unmet  clinical  need
to  reﬁne  therapy  beyond  GOLD  and  other  international  and
national  guidelines.This  paper  discusses  and  proposes  stepwise  and  ‘‘hit
hard’’  therapeutic  approaches  for  COPD  patients  based  on
their  GOLD  group.  An  alternative  treatment  approach,  based
on  phenotypes,  is  addressed  elsewhere.29 We  suggest  two
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ubgroups  for  GOLD  A  and  GOLD  B  patients,  with  different
herapeutic  approaches.  Finally,  we  conclude  that,  in  COPD,
herapy  should  be  tailored  to  the  patient,  taking  into  consid-
ration  co-morbidities,  presence  of  hyperinﬂation,  history
f  chronic  bronchitis,  levels  of  physical  activity,  and  each
ndividual  patient  characteristics.
OLD A patients
t  is  difﬁcult  to  identify  asymptomatic  GOLD  A  patients  with
o  exacerbations,  given  that  they  have  no  reason  to  seek
edical  help.  Spirometric  screening  of  asymptomatic  indi-
iduals  is  not  supported  by  evidence,  although  in  individuals
ver  40  years  old  and  with  a  smoking  history  of  >10  pack
ears,  spirometry  may  be  performed  with  the  aim  of  early
iagnosis.1 Indeed,  some  of  these  patients  are  identiﬁed
uring  screenings,  but  many  of  those  who  are  not  eligible  for
creening  (e.g.,  non-smokers),  may  remain  undiagnosed.11
lso,  these  patients  tend  to  underestimate  their  symptoms
nd  adapt  their  daily  activities  by  exercise  self-limitation,1
ence  reporting  to  be  asymptomatic.  These  unidentiﬁed
atients  cannot  receive  the  early  treatment,  which  has  been
hown  to  be  beneﬁcial.6,11,14
dentiﬁcation  of  GOLD  A  patients
esides  screening,  these  patients  are  mainly  identiﬁed  in
our  situations:  (a)  in  clinical  visits  for  other  causes  or
omplaints;  (b)  when  they  are  subjected  to  tests  for  non-
espiratory  reasons;  (c)  in  the  emergency  room  due  to
n  acute  episode;  or  (d)  during  pre-surgery  testing.  Once
dentiﬁed,  it  is  imperative  not  to  lose  these  patients  to
ollow-up,  as  they  will  eventually  evolve  to  other  GOLD
roup  and  therapy  will  have  to  be  adjusted.  A  correct  diag-
osis  is  of  the  utmost  importance,  since  it  leads  to  both
ndertreatment  and  overtreatment  (e.g.,  COPD  diagnosed
s  asthma).
We  suggest  an  active  case-ﬁnding  approach  for  the  iden-
iﬁcation  of  GOLD  A  patients.  We  further  propose  that  these
atients  are  ﬂagged  whenever  they  are  diagnosed  and,
hereafter,  that  they  are  managed  by  their  general  prac-
itioner,  in  close  cooperation  with  a  pulmonologist.
ecommended  therapeutic  approach  for  GOLD  A
atients
iven  that  these  patients  are  often  excluded  from  Ran-
omized  Clinical  Trials  (RCTs),  there  are  no  systematic  data
vailable  on  which  therapy  should  be  used  or  how  they  will
espond.6 Should  they  be  treated?  When?  With  which  med-
cation  and  how?  How  will  they  progress  with  or  without
herapy?  A  study  based  on  the  ECLIPSE  cohort  showed  that,
t  3  years  follow-up,  57%  of  patients  initially  assigned  to
OLD  A  remained  in  the  A  group,  whilst  the  remaining  43%
rogressed  to  other  GOLD  groups.13 Based  on  this  study,  all
OLD  A  patients  should  receive  treatment.
Current  guidelines  generally  recommend  for  these
atients  smoking  cessation,  physical  activity  programs,  and
nﬂuenza  and  pneumococcal  vaccination.  Also,  the  use
f  a  short-acting  beta-agonist  (SABA)  or  a  short-acting
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uscarinic  antagonist  (SAMA)  as  needed  is  mostly  consen-
ual,  although  LABA  or  LAMA  may  be  used  as  alternative
herapies.1--5 Some  authors  speculate  that  early  intervention
ith  long-acting  bronchodilators  may  improve  patient-
eported  outcomes.11 However,  one  major  issue  with  these
atients  is  compliance  to  long-term  drugs,6 and  patient  edu-
ation  is  fundamental  in  delaying  COPD  evolution.
In  GOLD  A  patients,  both  phenotype3,6,30 and  co-
orbidities1--5 should  be  taken  into  account  when  choosing
etween  a  LABA  or  a  LAMA,  with  the  aim  of  achieving  the
est  outcomes  and  delaying  disease  progression.  Both  LAMAs
nd  LABAs  have  shown  similar  proﬁles  regarding  FEV1 and
yspnea  improvement,  exercise  tolerance,  exacerbations
eduction  and  safety.21,23,24,26,31--40 However,  there  is  some
vidence  that  LAMAs  may  delay  lung  function  decline34,35
nd  decrease  all-cause  mortality,34 and  may  be  more  effec-
ive  than  LABAs  in  preventing  exacerbations.41 Despite  this,
nd  although  LABAs  do  not  seem  to  inﬂuence  mortality,42
wo  studies  showed  superiority  in  providing  better  symp-
omatic  improvement  than  a  LAMA.43,44 These  data  suggest
hat  LAMAs  should  be  preferred  for  patients  at  higher  risk
f  exacerbations,  whilst  LABAs  would  be  better  for  symp-
omatic  control,  although  it  depends  on  the  individual
linical  response  of  each  patient.  If  a  LABA  is  chosen,  inda-
aterol  may  be  preferable  to  other  commercially  available
ABAs  since,  besides  having  all  the  above  mentioned  advan-
ages  of  LABAs,  it  is  the  only  once-daily  LABA  with  studies
esigned  to  investigate  exacerbations45,46 and  proved  able  to
educe  them,  although  in  moderate  to  severe  patients.39,40
However,  evidence  is  still  too  scarce  to  propose  a  recom-
endation  between  a  LABA  and  a  LAMA.  Also,  the  ﬁnancial
spect  should  not  be  disregarded  when  choosing  between
 LABA  or  a  LAMA,  as  some  patients  may  not  be  able  to
fford  some  therapies  and  respond  well  to  more  affordable
lternatives.  Dual  bronchodilation  is  not  an  option  for  these
atients.
Finally,  given  the  heterogeneity  of  COPD,  even  patients
lassiﬁed  as  belonging  to  the  A  group  show  a  large  variability.
We  propose  that  group  A  patients  need  to  be  sub-divided
nto  two  groups,  AX1  and  AX2,  and  the  therapeutic  approach
hould  be  based  on  this  subdivision  --  Table  1.
We  further  recommend  that,  if  a  LABA  is  chosen,  inda-
aterol  may  be  preferable  as  it  also  reduces  the  rate  of
xacerbations.
We  also  recommend  that  therapy  should  be  tailored
o  the  patient,  taking  into  consideration  co-morbidities,
Table  1  Proposed  division  of  GOLD  A  patients  in  two  sub-
groups  and  respective  therapeutic  approaches.
Sub-group  characteristics  Therapeutic  approach
AX1:  FEV1 >  80%;
no worsening  of  FEV1 in
annual  assessment
SABA  or  SAMA  only  SOS
AX2: 50%  <  FEV1 <  80%;
and/or  worsening  of  FEV1 in
annual  assessment
LABA  or  LAMA
FEV1 -- forced expiratory volume in 1 second; SABA -- short act-
ing 2-agonist; SAMA -- short acting muscarinic antagonist; LABA
-- long acting 2-agonist; LAMA -- long acting muscarinic antag-
onist.
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resence  of  hyperinﬂation,  history  of  chronic  bronchitis,
evels  of  physical  activity  and  adverse  effects  of  each  drug.
Finally,  all  COPD  patients  should  be  offered  a  completely
ree  smoking  cessation  program,  including  consultations  and
herapy.
OLD B patients
urrent  guidelines  generally  recommend  for  these  patients
moking  cessation,  physical  activity  programs,  inﬂuenza  and
neumococcal  vaccination,  and  pulmonary  rehabilitation.1--5
ll  guidelines  agree  that  bronchodilators  are  the  baseline
herapy  for  all  stages  of  COPD,  but  the  choice  of  which
ronchodilator  to  use  is  left  to  the  physician.12 Also,  most
uidelines  generally  recommend  a  stepwise  approach,  and
ual  bronchodilation  only  when  one  bronchodilator  is  not
ufﬁcient  to  provide  satisfactory  symptom  relief.12 GOLD
ecommends  LAMA  or  LABA  as  the  ﬁrst  choice  medication
nd  LAMA  +  LABA  as  the  alternative  choice.2 If  indeed  the
hoice  is  a  stepwise  approach,  then  which  long-acting  bron-
hodilator  should  be  used,  a  LABA  or  a  LAMA?  As  already
iscussed  above,  evidence  is  still  too  scarce  to  propose  a
ecommendation.
On  the  other  hand,  Agusti  and  Fabbri  defend  the  ‘‘hit
ard’’  approach  with  dual  bronchodilation  for  GOLD  B
atients,17 and  there  are  several  arguments  in  favor
f  this  approach.  Group  B  and  C  patients  show  a  simi-
ar  risk  of  all-cause  mortality,13 suggesting  that  a  more
ggressive  treatment  approach  should  be  used  in  these
atients.  Also,  many  patients  receiving  long-acting  bron-
hodilator  monotherapy  continue  to  experience  signiﬁcant
ymptoms,18 and  dual  bronchodilation  provides  better
ymptomatic  relief,12,23,24 improves  FEV1 in  patients  with
oderate-to-severe  COPD,23,24,47 and  improves  health
tatus.23 Moreover,  reduction  of  hyperinﬂation,  as  achieved
ith  maximal  (dual)  bronchodilation,  increases  exercise
olerance,12,31 and  higher  levels  of  physical  activity  are
ssociated  with  a  better  functional  status48 and  reduced
isk  of  hospitalizations  and  mortality,49 even  at  levels  as  low
s  the  equivalent  to  walking  or  cycling  2  h/week.50 Also,
t  has  been  reported  that  objectively  measured  physical
ctivity  is  the  strongest  predictor  of  all-cause  mortality  in
atients  with  COPD.51 Therefore,  it  can  be  speculated  that
ual  bronchodilation  will  have  both  short-  and  long-term
eneﬁcial  effects  in  COPD  patients.  In  patients  who  will
eneﬁt  from  dual  bronchodilation,  LAMA/LABA  ﬁxed-dose
ombinations  are  expected  to  become  the  new  standard  in
OPD  treatment.9 In  GOLD  2  or  3  patients,  with  or  without
 history  of  exacerbations,  dual  bronchodilation  with  once-
aily  indacaterol/glycopyrronium  (IND/GLY)  has  clinically
eaningful  improvements  in  symptomatic  parameters
ersus  a  salmeterol/ﬂuticasone  combination  (SFC)21,22 and
iotropium,23 and  is  superior  to  treatment  with  its  mono-
omponents,  indacaterol  and  glycopyrronium,23 suggesting
he  existence  of  synergistic  activity  between  the  LABA  and
he  LAMA.11 IND/GLY  also  provided  superior  improvements
n  patient-reported  dyspnea  and  lung  function  versus
lacebo  and  tiotropium.24 Moreover,  indacaterol  and  gly-
opyrronium  show  a  very  fast  and  long-lasting  (about  24  h)
elaxation  of  airway  smooth  muscle.12 There  are  several
otential  advantages  and  beneﬁcial  effects  of  having  a
ombination  of  LABA  +  LAMA  on  the  same  device.52
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Table  2  Proposed  division  of  GOLD  B  patients  in  two  sub-
groups  and  respective  therapeutic  approaches.
Sub-group
characteristics
Therapeutic  approach
BX1:  mMRC  =  2;  AND
FEV1 >  70%;
AND  no  cardiovascular
co-morbidities
a)  if  not  medicated,
initiate  LABA  or  LAMA
BX2: mMRC  >  2;  OR
FEV1 <  70%;
OR  with  cardiovascular
co-morbidities
LABA  +  LAMA  (‘‘hit  hard’’
approach)  +  rehabilitation
with  exercise  training
mMRC -- modiﬁed Medical Research Council dyspnea scale; FEV
Table  3  Proposed  therapeutic  approach  for  C  and  D
patients.
C/D  Sub-group  Therapeutic  approach
C1  LAMA
D1 LAMA  +  LABA
C2 LABA  +  ICS
D2 LABA  +  ICS  +  LAMA
C3, D3  LABA  +  ICS  +  LAMA
C1, D1 -- patients at high risk due to poor function; C2, D2 --
patients at high risk due to exacerbations; C3, D3 -- patients at
-
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-- forced expiratory volume in 1 second; LABA -- long acting 2-
agonist; LAMA -- long-acting muscarinic antagonist.
Finally,  given  the  heterogeneity  of  COPD,  even  patients
classiﬁed  as  belonging  to  the  B  group  show  large  variability.
We  propose  that  group  B  patients  need  to  be  sub-divided
into  two  groups,  BX1  and  BX2,  and  the  therapeutic  approach
should  be  based  on  this  subdivision  --  Table  2.
We  further  recommend  that,  when  the  treatment
of  choice  is  dual  bronchodilation,  a  combination  of
LABA  +  LAMA  on  the  same  device  is  preferable.
GOLD C and D patients
In  addition  to  all  general  recommendations  for  GOLD  B
patients,1--5 guidelines  suggest:  LAMA  and/or  LABA,  with  or
without  ICS,1,2,4 with  ICS  recommended  for  patients  with
frequent  exacerbations  that  are  not  adequately  controlled
by  long-acting  bronchodilators;2,4 a  stepwise  or  step-up
approach,  or  immediate  triple  therapy,  depending  on  fre-
quency  of  exacerbations;5 no  recommendation  for  ICS  on
the  non-exacerbator  patient  phenotype.3 Agusti  &  Fabbri
propose  a  stepwise  or  step-up  approach  depending  on  dys-
pnea  and  risk  of  exacerbations,  respectively.17 A  recent
analysis  showed  that,  in  current  clinical  practice,  how-
ever,  group  D  patients  are  more  frequently  prescribed
triple  therapy,  regardless  of  pulmonary  function  and  risk  of
exacerbations,16 which  is  contrary  to  what  the  guidelines
recommend.
Regarding  dual  bronchodilation,  several  randomized  clin-
ical  trials  in  GOLD  2  to  4  patients,  with  or  without  a  history
of  exacerbations,  showed  that  dual  bronchodilation  with
IND/GLY  improves  symptoms,21--24,37 and  prevents  moderate
to  severe  COPD  exacerbations.37 In  the  SHINE,23 BLAZE24 and
SPARK37 studies,  patients  already  on  ICS  therapy  at  base-
line  maintained  the  ICS  during  the  study,  whereas  in  the
ILLUMINATE21 and  LANTERN22 studies  patients  on  ICS  ther-
apy  before  study  start  underwent  a  washout  period.  Taken
together,  these  data  suggest  that  dual  bronchodilation  is  an
appropriate  treatment  option  for  patients  with  severe  and
very  severe  COPD.C  and  D  subgroups
Therapeutic  options  have  to  consider  the  three  C  and  D  sub-
groups:
s
t
s
chigh risk due to both poor function and exacerbations; LABA --
long acting 2-agonist; LAMA -- long-acting muscarinic antago-
nist; ICS - inhaled corticosteroid.
 C1,  D1  (high  risk  due  to  poor  function)
 C2,  D2  (high  risk  due  to  exacerbations)
 C3,  D3  (high  risk  due  to  both  poor  function  and  exacerba-
tions)
We  propose  that  the  therapeutic  approach  is  based  on
hese  subgroups  --  Table  3. When  the  treatment  of  choice  is
ual  bronchodilation,  a  combination  of  LABA  +  LAMA  on  the
ame  device  is  preferable.  For  C1  and  D1  patients,  a  step-
ise  or  ‘‘hit  hard’’  approach  should  be  decided  depending
n  symptoms,  with  the  ‘‘hit  hard’’  approach  recommended
n  strongly  symptomatic  patients.  For  C2,  D2,  C3  and  D3
atients,  a  step-up  approach  or  immediate  triple  therapy
hould  be  decided  depending  on  the  frequency  of  exacer-
ations.  We  suggest  the  patient  to  be  re-assessed  every
 months  during  a  one  year  period  after  initiation  of  ICS
spirometry,  the  Modiﬁed  Medical  Research  Council  Dyspnea
cale  (mMRC),  the  COPD  Assessment  Test  (CAT),  inﬂamma-
ion,  symptoms).  We  further  recommend  that,  if  there  were
o  exacerbations  during  12  months,  COPD  was  stable,  and
ssessed  parameters  are  within  the  expected  range,  with-
rawal  of  ICS  could  be  considered.
CS
lthough  ICS  are  not  indicated  for  patients  without
xacerbations,2--5,17 ICS/LABA  or  even  triple  therapy  is
idely  prescribed  in  real-life  management  of  COPD,  even  in
atients  with  mild  or  moderate  COPD  severity.  Both  General
ractitioners  and  specialists  in  respiratory  medicine  often
se  triple  therapy  even  for  patients  who  are  not  suffer-
ng  from  severe  COPD.8 Although  the  reasons  for  this  are
nclear,  we  speculate  that  this  is  mainly  due  to  the  gener-
lized  idea  that  a  patient  taking  ICS  will  be  more  controlled
han  a  patient  who  is  not  on  ICS  therapy,  and  will  not  exac-
rbate  or  decompensate.  This  is  not  true.  In  fact,  patients
ho  do  not  need  ICS  therapy  will  be  overmedicated,  will  not
eneﬁt  from  triple  therapy,  and  will  suffer  all  the  possible
dverse  events  of  ICS,  namely  pneumonia.
A  recent  review  from  UK  general  practice  showed
hat,  in  2009,  patients  in  all  GOLD  stages  were  receiv-
ng  triple  therapy.15 The  question  of  whether  the  less
evere  patients  were  frequent  exacerbators,  and  thus  being
reated  according  to  the  current  guidelines,  remained  unan-
wered.  Another  recent  analysis  conﬁrmed  that,  in  current
linical  practice,  ICS  are  indeed  used  inappropriately.16
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hese  reports  indicate  that  ICS  prescription  does  not  fol-
ow  the  current  guidelines  and  thousands  of  patients  may
e  overtreated.
ithdrawal  from  ICS
f  patients  are  indeed  being  overtreated,  then  they  will  not
nly  be  subjected  to  the  ICS’  numerous  side  effects  but  they
ill  also  not  beneﬁt  from  the  ICS,  rendering  the  risk/beneﬁt
atio  of  the  ICS  too  high  to  justify  its  use.  A  systematic
eview  from  2011  on  trials  with  withdrawal  of  ICS  found
o  evidence  that  withdrawing  patients  from  ICS  in  routine
ractice  led  to  important  deterioration  of  outcomes,  namely
requency  of  exacerbations  and  exercise  tolerance.  Only  one
f  the  included  trials  reported  a  signiﬁcant  decline  in  lung
unction.53 The  ILLUMINATE21 and  the  LANTERN22 studies
howed  that,  in  GOLD  2  and  3  patients  with  or  without  one
oderate  or  severe  exacerbation  in  the  previous  year,  ICS
an  be  safely  withdrawn,  and  once-daily  IND/GLY  provided
igniﬁcant,  sustained,  and  clinically  meaningful  improve-
ents  in  lung  function  versus  twice-daily  SFC.  In  addition,
ND/GLY  provided  signiﬁcant  symptomatic  beneﬁt  and  was
uperior  to  SFC  in  achieving  bronchodilation  and  reducing
he  rate  of  exacerbations.  Another  study  in  which  ICS  ther-
py  was  either  switched  or  withdrawn,  in  patients  with
oderate  to  severe  COPD,  showed  that  ICS  can  be  safely
iscontinued,  and  the  addition  of  ﬂuticasone--salmeterol  to
iotropium  may  improve  lung  function  and  decrease  hospi-
alizations,  but  does  not  affect  rates  of  exacerbations.26 The
PTIMO  study,27 a  real-life  study,  showed  that  ICS  may  be
ithdrawn,  provided  appropriate  therapy  with  bronchodila-
ors  is  maintained,  but  the  WISDOM  study54 showed  that
CS  withdrawal  had  no  effect  on  exacerbations  but  led  to  a
ecrease  in  pulmonary  function.  The  different  results  from
he  OPTIMO  and  WISDOM  studies  may  lie  in  one  simple  fact:
n  the  OPTIMO27 study  patients  had  an  average  FEV1≈71%
redicted,  being  probably  non-exacerbator  GOLD  B  patients,
nd  therefore  did  not  need  ICS,  whilst  the  WISDOM54 study
atients  had  much  more  severe  airway  limitation  (FEV1≈34%
redicted,  GOLD  3  and  4),  probably  ﬁtting  the  criteria  for
CS  use,  and  were  thus  affected  by  withdrawal.  Another
xplanation  for  these  results  lies  in  the  design  of  the  WIS-
OM  study,  where  even  patients  who  had  never  been  on
CS,  received  an  ICS-containing  triple  therapy  for  6  weeks
efore  randomization.  Moreover,  the  OPTIMO  study  explic-
tly  excludes  patients  with  a  ‘‘history  of  asthma’’,  whilst  the
ISDOM  study  excludes  patients  with  a  ‘‘current  diagnosis
f  asthma’’,  which  makes  it  possible  for  patients  with  ACOS
o  be  included  in  the  WISDOM  study.
A  very  recent  UK  Primary  Care  Setting  retrospective
tudy  shows  that,  in  newly  diagnosed  COPD  patients,  with-
rawal  from  ICS  is  common  after  12  or  24  months  of  therapy
nitiation.28 Unfortunately,  and  although  included  patients
ere  classiﬁed  as  GOLD  1  to  4,  treatment  approaches  used
ere  not  stratiﬁed  by  GOLD  stage.
Regardless  all  available  evidence,  there  is  a  generalized
oncern  among  physicians  that,  if  a  patient  is  withdrawn
rom  ICS,  that  patient  will  decompensate  or  exacerbate.
ven  if  the  patient  is  re-assessed  and  does  not  have  indi-
ations  for  ICS,  the  reluctance  to  withdraw  remains.  This
oncern  stems  mainly  from  the  results  of  the  TORCH19,20,42
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rial,  which  convinced  the  community  of  physicians  that  ICS
mproves  several  outcomes,  slows  disease  progression  and
educes  moderate-to-severe  exacerbations,  even  if  failing
o  show  a  beneﬁcial  effect  of  ICS  on  all-cause  mortality
ates.  However,  in  light  of  more  recent  data,  as  presented
bove,  there  is  no  evidence-based  reason  for  such  a  concern.
Another  hindrance  to  deciding  whether  to  withdraw
rom  ICS  or  not  is  misdiagnosis,  e.g.  COPD  misdiagnosed  as
sthma,  or  suspicion  of  the  ACOS  phenotype.  The  only  way
o  overcome  this  hindrance  is  to  attain  a  proper  diagnosis.
Finally,  patients  prefer  to  be  withdrawn  from  ICS
ue  to  the  general  perception  that  corticosteroids  are
‘dangerous’’  --  and  indeed  they  can  be,  if  not  properly
rescribed.
We  recommend  that  A  and  B  patients  without  exacerba-
ions,  who  are  overtreated  with  ICS,  should  be  withdrawn
rom  ICS  in  order  to  optimize  therapy  and  reduce  exces-
ive  medications,  provided  they  are  not  ACOS,  and  kept  on
lose  surveillance.  C  and  D  patients  without  exacerbations
hould  also  be  withdrawn  from  ICS,  with  re-assessments  rec-
mmended  every  3  months  during  a  one  year  period.
ow  to  withdraw  from  ICS?
he  two  options  are  withdrawal  of  ICS  with  or  without
apering  off.  The  UK  Primary  Care  Setting  retrospective
tudy  does  not  specify  how  withdrawal  from  ICS  was
chieved.28 Both  the  ILLUMINATE  study21 and  the  LANTERN
tudy22 mention  a  washout  period  of  up  to  7  days,  but
lso  do  not  specify  if  this  period  was  with  or  without
apering  off.  Aaron  et  al.  also  do  not  specify  how  ICS  was
iscontinued.26 The  OPTIMO  study27 does  not  mention  how
CS  was  withdrawn,  but  the  WISDOM  study54 does  specify
hat  ICS  was  tapered  off  over  a  12  week  period.
Given  the  lack  of  concrete  data,  we  can  only  speculate
hat  if  a patient  does  not  need  ICS,  then  there  is  no  need
o  taper  off.  In  addition,  as  it  is  a  non-systemic  medication,
here  is  no  scientiﬁc  rationale  for  tapering  off.
We  recommend  that  patients  with  no  exacerbations  dur-
ng  12  months  and  who  are  stable  should  be  withdrawn  from
CS.  Tapering  off  is  not  necessary  and  ICS  should  be  with-
rawn  in  a  single  step.  We  suggest  GOLD  A  and  B patients
e  re-assessed  every  6  months,  and  Gold  C  and  D  patients
very  3  months,  during  a  one  year  period  after  ICS  with-
rawal  (spirometry,  mMRC,  inﬂammation,  symptoms).  We
urther  recommend  that,  in  C  and  D  patients,  if  there  were
xacerbations  during  6  months,  or  if  pulmonary  function
onsistently  decreases,  there  should  be  a  step-up  with  ICS.
hich  patients  will  beneﬁt  from  ICS?
here  is  a  need  for  biomarkers  of  response  to  therapy
nd  disease  progression,  so  that  the  moment  of  therapeu-
ic  adjustments  can  be  determined  in  a  timely  way.  Some
iomarkers  of  disease  activity  and  progression  have  been
roposed,55,56 but  much  more  research  needs  to  be  done
efore  these  are  clinically  applicable,  and  can  guide  per-
onalized  management  of  COPD  patients.  Perhaps  the  most
romising  available  marker  is  sputum  eosinophilia,  and  most
ecently  also  blood  eosinophilia.57 COPD  patients  with  spu-
um  eosinophilia  >  3%  seem  to  respond  better  to  both  ICS
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and  systemic  corticosteroids.10,58--61 As  for  circulating  levels
of  C-reactive  protein  (CRP),  results  from  different  studies
are  controversial,  and  CRP  may  not  be  a  suitable  biomarker
in  COPD,  due  to  its  low  speciﬁcity  and  high  variability.58
We  recognize  that  there  are  currently  no  accurate
biomarkers  to  guide  therapy  in  COPD.  We  propose  that  CAT
should  be  used  in  all  consultations,  in  order  to  monitor  ther-
apeutic  response,  given  it  is  a  predictor  of  exacerbations.
ICS  class,  dose  and  pneumonia
The  consensus  is  that  ICS  use  increases  the  risk  of  pneumonia
in  patients  with  COPD,1,2,4,20--22,36,62 and  even  a  recent  ICS,
ﬂuticasone  furoate,  has  been  associated  with  an  increased
pneumonia  risk  and  deaths  from  pneumonia  in  COPD
patients.62--64 However,  some  studies  ﬁnd  a  very  small  differ-
ence  in  the  risk  of  pneumonia  with  ICS.21,22,26 These  dissimi-
lar  results  may  stem  from  the  fact  that  some  studies  are  too
short  for  patients  to  develop  pneumonia,  and/or  that  sev-
eral  ICS  classes  and  doses  are  used  in  different  studies.  Both
ﬂuticasone  and  budesonide  have  been  reported  to  increase
the  risk  of  pneumonia,64--67 but  results  concerning  a  dose
effect  range  from  no  difference  between  ﬂuticasone  and
budesonide,65 to  ﬂuticasone  being  associated  with  a  higher,
dose  dependent  risk,  when  compared  to  budesonide,66 to
ﬂuticasone  not  being  dose  dependent,  while  budesonide
shows  a  signiﬁcant  difference  between  the  two  commonly
used  doses.67 The  general  dose-effect  of  ICS  on  pneumo-
nia  risk  has  been  conﬁrmed  in  a  large  USA  retrospective
cohort  study,  but  the  use  of  several  ICS  classes  precludes  any
conclusion  regarding  speciﬁc  ICS  class-related  dose-effect.68
Results  concerning  the  true  effect  of  different  ICS  classes
and  doses  on  the  risk  of  pneumonia  remain  inconclusive.
More  studies  are  needed  to  allow  an  evaluation  of  whether
different  classes  of  ICS  are  associated  with  different  pneu-
monia  risk  in  COPD  patients.
Given  the  controversy  surrounding  ICS  therapy  in  COPD
patients,  we  suggest  that  a  withdrawal  or  step-up  approach
should  take  into  account  the  above  recommendations  but
be  tailored  to  the  patient,  taking  into  consideration  each
individual  patient  characteristics.
Conclusions
Both  stepwise  and  ‘‘hit  hard’’  approaches  have  bene-
ﬁts.  Only  a  careful  patient  selection  will  determine  which
approach  is  better,  and  which  patients  will  beneﬁt  the  most
from  each  approach.  In  COPD,  therapy  should  be  tailored  to
the  patient,  taking  into  consideration  co-morbidities,  pres-
ence  of  hyperinﬂation,  history  of  chronic  bronchitis,  levels
of  physical  activity,  and  each  individual  patient  characteris-
tics.
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